# GlaxoSmithKline Pharmaceuticals (GLAXO) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/glaxo

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,530
- Change: +1.19%
- As of: 2026-11-06
- 1D return: +1.19%
- 5D return: +1.43%
- 1M return: -0.17%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

GLAXO is trading at ₹2,530.00 on 2026-11-06, situated in a complex technical environment where short-term price structure conflicts with longer-term momentum. The stock is currently above its 20-period and 200-period Simple Moving Averages (SMAs), suggesting some underlying support, but remains below key exponential moving averages (EMAs) and the Supertrend indicator across daily, weekly, and monthly timeframes. This positioning indicates that while the price has recovered slightly from recent lows, the dominant trend remains bearish with developing to weak conviction (ADX values of 20.08 daily, 21.79 weekly, and 15.87 monthly).

Momentum is mixed: the 1-month return is -8.2%, yet the stock has gained +1.2% over the last day and sits +66.1% into its 20-day range. An extreme downward volume anomaly occurred on 2026-11-04 (-1.7% return, 4.37x volume ratio), which coincided with a Bearish Engulfing pattern, signaling significant selling pressure that may still be digesting. Conversely, an active Inside Bar formation on the monthly chart suggests consolidation.

Near-term risk is defined by immediate resistance at ₹2,551.07 (0.83% above) and support at ₹2,522.53 (0.30% below). The stock carries high annualized volatility (+34.6%) and is currently in a -27.0% drawdown from its available high. A break above ₹2,551.07 with sustained volume would be required to challenge the bearish Supertrend alignment; failure to hold above ₹2,522.53 could expose lower supports at ₹2,501.80.

- Trend Conflict: Price is above 20/200 SMAs but below EMAs and Supertrend across all timeframes, indicating a bearish macro trend with short-term structural support.
- Recent Volatility: An extreme volume-price anomaly on 2026-11-04 (-1.7%, 4.37x volume) accompanied a Bearish Engulfing pattern, highlighting persistent selling interest.
- Key Levels: Immediate resistance at ₹2,551.07 (+0.83%) and support at ₹2,522.53 (-0.30%). Monthly consolidation is signaled by an active Inside Bar.
- Risk Metrics: High volatility (+34.6% annualized) and a current drawdown of -27.0% from the available high suggest elevated downside risk.

- Inside Bar
- Bearish Engulfing Reversal
- Outside Bar
- Bullish Engulfing Reversal

### News Context

GlaxoSmithkline Pharmaceuticals (GLAXO) reported unaudited financial results for the quarter ended September 30, 2026, on November 4, 2026. Standalone revenue rose 21% to ₹1,180 crore, driven by sales execution and a favorable prior-year base. Profit after tax before exceptional items increased 33% to ₹335 crore, with margins expanding by 260 basis points to 29%. However, EBITDA growth was moderated to 20%, as gross-margin pressure from currency depreciation and higher input costs offset price increases. The Board approved these figures on November 3, and they were disseminated via newspaper publications and investor presentations on November 5. As of November 6, the stock closed at ₹2,530, trading within a bearish technical trend characterized by an annualized volatility of 34.6% and a current drawdown of -27.0%.

- Q2 FY27 standalone revenue grew 21% YoY to ₹1,180 crore, while PAT before exceptional items rose 33% to ₹335 crore.
- EBITDA margin contracted by 50 basis points to 34% due to currency depreciation and higher input costs, despite a 20% rise in absolute EBITDA.
- The company disclosed Q2 results via NSE/BSE filings on November 5, following Board approval on November 3.
- As of November 6, GLAXO shares closed at ₹2,530, with technical indicators showing a bearish daily supertrend and high volatility (34.6%).

- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL
- GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation
- GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL

### Official Filings

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reported strong financial performance for Q2 and H1 FY27, with standalone revenue rising to ₹1,180 crore in the quarter (up 21%) and net profit reaching ₹25,500 lakhs. The company also announced a change in statutory auditors, appointing M/s Walker Chandiok & Co LLP for a five-year term from FY 2027-28 to FY 2031-32, subject to shareholder approval. Additionally, Mr. Sandeep Seth was appointed as Head - Ethics & Compliance. These developments provide updated financial visibility and governance changes, while routine filings such as auditor appointment notices and earnings call recordings were also submitted to the exchanges.

- Q2 FY27 Standalone Revenue: ₹1,180 crore (+21% YoY); EBITDA: ₹400 crore (+20% YoY, 34% margin).
- H1 FY27 Standalone Net Profit: ₹58,795 lakhs; Q2 Standalone Net Profit: ₹25,500 lakhs.
- Auditor Change: M/s Walker Chandiok & Co LLP appointed as Statutory Auditors for FY 2027-28 to FY 2031-32 (Board approved, pending shareholder approval).
- Leadership Update: Mr. Sandeep Seth appointed as Head - Ethics & Compliance w.e.f. November 3, 2026.

- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115250_Clause_47.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115416_AnalystMeetOutcome_-_Video.pdf)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261105_124119828.xml)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026130703_Analyst_Meet_Final_Presentation.pdf)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220807345.xml)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220841247.xml)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026220628_AnalystMeetOutcome_-_Audio.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026184904_Outcome_of_Meeting.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company. |SUBJECT: Change in Auditors](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185423_Outcome_of_Meeting.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Appointment of Saneep Seth as Other of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185321_Outcome_of_Meeting.pdf)

### Fundamentals

Glaxosmithkline Pharmaceuticals (NSE: GLAXO) demonstrated a strong operational rebound in Q2 FY2026-27, with revenue from operations rising to ₹1,184 crore, up from ₹938 crore in Q1. Net profit followed suit, increasing to ₹336 crore compared to ₹237 crore in the previous quarter. This sequential improvement aligns with the TTM sales growth of 12% and profit growth of 19%, indicating sustained momentum after a slight dip in YoY sales growth during Sep 2025 (-3%).

Earnings quality remains robust, supported by a Cash from Operating Activity (CFO) of ₹903 crore for Mar 2026 and a CFO/EBITDA ratio of 93%. The balance sheet shows increased liquidity, with cash and equivalents nearly doubling to ₹651 crore as of Sep 2026, while borrowings rose modestly to ₹39 crore. Promoter holding remained stable at 75%, with DIIs increasing their stake to 8.47%.

The most critical checkpoint is the sustainability of this margin expansion and working capital efficiency. With Days Payable decreasing to 154 days in Mar 2026 from 186 days in Mar 2025, management must demonstrate that improved cash conversion does not come at the cost of supplier relationships or inventory buildup, especially as Fixed Assets grew to ₹293 crore.

- Q2 FY2026-27 Revenue From Operations reached ₹1,184 crore, a 26% sequential increase from Q1's ₹938 crore.
- Net Profit rose to ₹336 crore in Q2 FY2026-27, up from ₹237 crore in Q1, supporting TTM profit growth of 19%.
- Cash and cash equivalents nearly doubled to ₹651 crore as of Sep 2026, up from ₹340 crore in Sep 2025.
- Days Payable decreased to 154 days in Mar 2026 from 186 days in Mar 2025, signaling tighter payables management.

### Bear Case

Technical indicators for Glaxosmithkline Pharmaceuticals (NSE) as of November 6, 2026, present a predominantly bearish setup across daily, weekly, and monthly timeframes. The stock is trading at ₹2,530.0, with Supertrend signals indicating a bearish direction on all three horizons. Momentum metrics show weakness, evidenced by the Minus DI exceeding Plus DI in both daily (21.7 vs 17.53) and weekly (23.36 vs 19.9) charts. The stock has experienced significant volatility, with an annualized volatility of +34.6% and a current drawdown of -27.0%, sitting within a maximum historical drawdown range of -39.3%. Recent performance reflects this pressure, with a -8.2% return over the last month and a -2.9% decline over the past year, despite a positive year-to-date return of +3.0%. Immediate support lies near ₹2,522.53, while resistance is clustered closely above at ₹2,551.07.

- Bearish trend alignment: Supertrend signals are bearish on daily, weekly, and monthly charts, with Minus DI consistently higher than Plus DI, signaling downward momentum.
- Significant drawdown risk: The stock is currently down -27.0% from recent peaks, approaching its maximum historical drawdown of -39.3%, with high annualized volatility of +34.6%.

- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115250_Clause_47.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115416_AnalystMeetOutcome_-_Video.pdf)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261105_124119828.xml)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026130703_Analyst_Meet_Final_Presentation.pdf)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220807345.xml)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220841247.xml)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026220628_AnalystMeetOutcome_-_Audio.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026184904_Outcome_of_Meeting.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company. |SUBJECT: Change in Auditors](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185423_Outcome_of_Meeting.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Appointment of Saneep Seth as Other of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185321_Outcome_of_Meeting.pdf)

### FAQs

**What were GlaxoSmithKline Pharmaceuticals' key financial results for Q2 FY27?**

For the quarter ended September 30, 2026, the company reported standalone revenue of ₹1,180 crore (up 21%) and EBITDA of ₹400 crore (up 20%, margin 34%). Profit after tax before exceptional items was ₹335 crore (up 33%, margin 29%). The Board approved these unaudited results on November 3, 2026.

**Why did EBITDA margins decline despite strong revenue growth?**

While revenue grew 21% due to sales execution and a favorable prior-year base, EBITDA margin contracted by 50 basis points to 34%. The company attributed this moderation primarily to gross-margin pressure from currency depreciation and higher input costs, which were only partly offset by price increases.

**How has the stock performed technically over recent periods?**

As of November 6, 2026, the stock closed at ₹2,530.0 with a market capitalization of approximately ₹42,355 crore. Technical indicators show a bearish trend across daily, weekly, and monthly timeframes. The stock is currently in a -27.0% drawdown from its maximum peak of -39.3%.

**What are the immediate support and resistance levels for the stock?**

The nearest support level is at ₹2,522.53 (0.30% below current price), followed by ₹2,501.80. Resistance levels are located at ₹2,551.07 (0.83% above), ₹2,573.20 (1.71% above), and ₹2,601.93 (2.84% above).

- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115250_Clause_47.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115416_AnalystMeetOutcome_-_Video.pdf)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261105_124119828.xml)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026130703_Analyst_Meet_Final_Presentation.pdf)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220807345.xml)
- [GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220841247.xml)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026220628_AnalystMeetOutcome_-_Audio.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026184904_Outcome_of_Meeting.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company. |SUBJECT: Change in Auditors](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185423_Outcome_of_Meeting.pdf)
- [GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Appointment of Saneep Seth as Other of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185321_Outcome_of_Meeting.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹2,522.53
- Risk regime: Price Risk Requires Attention

### Support levels
- 2501.8048828125
- 2458.496875
- 2336.75

### Resistance levels
- 2573.2
- 2680.2625
- 2701.9652343750004

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.19% |
| return_10 | +5.21% |
| return_1m | -8.17% |
| return_1y | -2.90% |
| return_20 | -0.17% |
| return_3m | -1.92% |
| return_5 | +1.43% |
| return_6m | +4.40% |
| return_since_start | +13.35% |
| return_ytd | +3.02% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -39.32% |
| annualized_volatility | +34.61% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# GlaxoSmithKline Pharmaceuticals Limited Q2 FY2026-27: Revenue rises 21%

Revenue from operations grew 20.8% year on year to ₹1,183.57 crore in the quarter ended 30 September 2026, while profit for the period increased 30.4% to ₹335.88 crore. Expenses grew at a slower 20.4%, and quarter-on-quarter revenue and profit also advanced from Q1 FY2026-27. At quarter-end, cash and cash equivalents were lower than at 31 March 2026, while current investments were higher.

## Revenue and total income

Revenue from operations was ₹1,183.57 crore, compared with ₹979.94 crore in Q2 FY2025-26 and ₹938.44 crore in Q1 FY2026-27—up 20.8% year on year and 26.1% quarter on quarter. Total income reached ₹1,256.35 crore, up from ₹1,013.51 crore a year earlier and ₹982.20 crore in the prior quarter. Other income was ₹72.78 crore in Q2 FY2026-27.

## Expenses

Total expenses increased 20.4% year on year to ₹797.01 crore and 20.8% from ₹659.75 crore in Q1 FY2026-27. The quarter’s expenses included ₹279.04 crore of purchases of stock in trade, ₹128.92 crore of materials consumed, ₹170.19 crore of employee benefit expense and ₹166.83 crore of other expenses. Other expenses were up 10.8% year on year and 7.0% quarter on quarter. Overall, expenses grew more slowly than revenue in both comparisons.

## Profit and earnings per share

Profit before tax was ₹459.34 crore, up 29.8% year on year from ₹354 crore in Q2 FY2025-26 and 42.5% from ₹322.45 crore in Q1 FY2026-27. Profit for the period rose 30.4% year on year to ₹335.88 crore, from ₹257.49 crore, and 41.6% quarter on quarter from ₹237.18 crore. Tax expense was ₹123.46 crore, including current tax of ₹121.77 crore.

Basic and diluted earnings per share were both ₹19.83. Basic EPS was ₹15.07 in Q2 FY2025-26 and ₹14 in Q1 FY2026-27; diluted EPS was ₹15.20 and ₹14, respectively. Trailing 12-month EPS was ₹66.77.

## Cash flow and liquidity

Reported operating cash flow was ₹311.44 crore, investing cash flow ₹220.33 crore and financing cash flow negative ₹983.07 crore. Reported free cash flow was ₹531.77 crore. Cash and cash equivalents stood at ₹650.75 crore on 30 September 2026, down from ₹1,102.05 crore on 31 March 2026. Current investments increased to ₹1,524.01 crore from ₹1,390.96 crore over the same dates.

## Balance sheet

Total assets were ₹3,968.58 crore at 30 September 2026, compared with ₹4,323.87 crore at 31 March 2026. Equity attributable to owners of the parent declined to ₹1,881.05 crore from ₹2,267.42 crore. Inventories rose to ₹554.39 crore from ₹457.55 crore, and trade receivables increased to ₹339.41 crore from ₹273.11 crore.

## Key Takeaway

Q2 FY2026-27 combined 20.8% year-on-year revenue growth with faster 30.4% growth in profit for the period, as expenses grew more slowly than sales. At the same time, quarter-end cash and equity were below their 31 March 2026 levels, while current investments, inventories and receivables were higher.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +75.00%
- FII holding: +4.75%
- DII holding: +8.47%
- Mutual fund holding: +6.07%
- Retail holding: +9.46%
- Promoter pledged: +0.00%

### Major reported shareholders

- GLAXO GROUP LIMITED — +35.99% (Overseas Corporate Bodies)
- GLAXOSMITHKLINE PTE LIMITED — +28.10% (Overseas Corporate Bodies)
- ESKAYLAB LIMITED — +6.94% (Overseas Corporate Bodies)
- BURROUGHS WELLCOME INTERNATIONAL LIMITED — +3.97% (Overseas Corporate Bodies)
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIF — +1.05%
- QUANT MUTUAL FUND-QUANT ELSS TAX SAVER FUND — +1.01%

## Official filings

- 2026-11-05 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115250_Clause_47.pdf)
- 2026-11-05 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_05112026115416_AnalystMeetOutcome_-_Video.pdf)
- 2026-11-05 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261105_124119828.xml)
- 2026-11-04 — Earnings Presentation: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026130703_Analyst_Meet_Final_Presentation.pdf)
- 2026-11-04 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220807345.xml)
- 2026-11-04 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261104_220841247.xml)
- 2026-11-04 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_04112026220628_AnalystMeetOutcome_-_Audio.pdf)
- 2026-11-03 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026184904_Outcome_of_Meeting.pdf)
- 2026-11-03 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185423_Outcome_of_Meeting.pdf)
- 2026-11-03 — Management Change: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_03112026185321_Outcome_of_Meeting.pdf)
- 2026-11-03 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1095_WebXMLFile_20261103_190420318.xml)
- 2026-11-03 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1095_WebXMLFile_20261103_190339720.xml)
- 2026-11-03 — Financial Results Filing: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752182_03112026074815_WEB.xml)
- 2026-11-03 — Financial Results Filing: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752180_03112026074804_WEB.xml)
- 2026-10-28 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1095_WebXMLFile_20261028_162129156.xml)
- 2026-10-28 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_28102026162413_Analyst_Meet.pdf)
- 2026-10-15 — Shareholding Disclosure: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1738702_15102026021804_WEB.xml)
- 2026-10-13 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1095_WebXMLFile_20261013_160446828.xml)
- 2026-10-13 — Board Meeting Notice: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1095_WebXMLFile_20261013_160446828.xml)
- 2026-10-13 — Board Meeting Notice: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_13102026160812_Board_Meeting_Intimation_-_Copy.pdf)
- 2026-10-13 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_13102026161043_Final_Share_reco.pdf)
- 2026-10-12 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_12102026163134_clause_74.pdf)
- 2026-09-25 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_1095_WebXMLFile_20260925_143800518.xml)
- 2026-09-25 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_25092026144154_Tradingwindowclosure.pdf)
- 2026-09-15 — Generic Announcement: GlaxoSmithKline Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAXO1924_15092026125437_Final_outcome.pdf)

## News and market events

- 2026-11-07 — MONEYCONTROL: **Buy GlaxoSmithKline Pharmaceuticals; target of Rs 2900: ICICI Securities** — ICICI Securities has issued a 'Buy' recommendation for GlaxoSmithKline Pharmaceuticals, setting a price target of Rs 2900. — [Source](https://www.moneycontrol.com/news/business/earnings/buy-glaxosmithkline-pharmaceuticals-target-of-rs-2900-icici-securities-14074304.html)
- 2026-09-28 — BUSINESS: **Volumes jump at Tata Teleservices (Maharashtra) Ltd counter** — Tata Teleservices (Maharashtra) Ltd saw volume of 691.36 lakh shares by 14:14 IST on NSE, a 40.56 fold spurt over two-week average daily volume of 17.05 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-jump-at-tata-teleservices-maharashtra-ltd-counter-126092800606_1.html)
- 2026-08-18 — Mint: **Stocks to buy for short term: Grasim, Quess Corp among 6 stocks experts recommend buying today for next 1-2 weeks** — Experts suggest capitalising on bullish momentum by targeting six stocks poised for growth over the next 1-2 weeks. With a focus on disciplined risk management, this article reveals key levels and potential upside for smart investors seeking short-term opportunities. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-buy-for-short-term-grasim-quess-corp-among-6-stocks-experts-recommend-buying-today-for-next-1-2-weeks-11787027051128.html)
- 2026-08-03 — CNBC-TV18: **GSK Pharma Q1 profit rises 16% as general medicines, vaccines drive growth** — The company's net profit stood at ₹237.1 crore for the first quarter of FY27, compared with ₹205 crore a year earlier. Revenue from operations increased 16.6% to ₹938 crore from ₹805 crore in the corresponding quarter last year. — [Source](https://www.cnbctv18.com/market/earnings/gsk-pharma-q1-profit-rises-16-as-general-medicines-vaccines-drive-growth-19960572.htm)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)

## Business profile

**Strategic vision:** Develops and delivers medicines and vaccines for global health.

### Business segments
- **Pharmaceuticals and Healthcare:** The company discovers, develops, and delivers medicines and vaccines across four key therapeutic areas. It offers a range of pharmaceutical products in India.

### Competitive strengths
- Research-based approach to medicine and vaccine development.
- Focus on specific therapeutic areas for specialized expertise.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Anthem Biosciences Limited (Healthcare)](https://faxioms.com/stocks/anthem) — +0.16%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/glaxo
Markdown representation: https://faxioms.com/stocks/glaxo?render=md